Database Query Results : , , MDM2

MDM2, Double Minute 2 homolog: Click to Expand ⟱
Source:
Type: oncoprotein
Oncoprotein MDM2, a major ubiquitin E3 ligase of tumor suppressor p53; overexpression of MDM2 in human cancers is associated with a poor prognosis.
- A gene that encodes a protein involved in the regulation of the p53 tumor suppressor. The p53 protein plays a crucial role in controlling cell cycle progression, DNA repair, and apoptosis (programmed cell death). MDM2 functions primarily as an E3 ubiquitin ligase, which means it tags p53 for degradation, thereby regulating its levels in the cell.
-MDM2 is often overexpressed in various tumors, leading to the inhibition of p53 activity. This can result in uncontrolled cell proliferation, evasion of apoptosis, and increased genomic instability, all of which contribute to tumorigenesis.
Scientific Papers found: Click to Expand⟱
1564- Api,    Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
- in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
MDM2↓, NF-kB↓, p65↓, P21↑, ROS↑, GSH↓, MMP↓, Cyt‑c↑, Apoptosis↑, P53↑, eff↓, Bcl-xL↓, Bcl-2↓, BAX↑, Casp↑, TumCG↓, TumVol↓, TumW↓,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
1532- Ba,    Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives
- Review, NA, NA
ROS↑, ER Stress↑, Ca+2↑, MMPs↓, Cyt‑c↑, Casp3↑, ROS↑, DR5↑, ROS↑, BAX↑, Bcl-2↓, MMP↓, Casp3↑, Casp9↑, P53↑, p16↑, P21↑, p27↑, HDAC10↑, MDM2↓, Apoptosis↑, PI3K↓, Akt↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IκB↓, IκB↑, BAX↑, Bcl-2↓, ROS⇅, BNIP3↑, p38↑, 12LOX↓, Mcl-1↓, Wnt?, GLI2↓, AR↓, eff↑,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
14- CUR,    Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway
- vitro+vivo, Pca, PC3
PI3K/mTOR/ETS2↓, MDM2↓, P21↑,
118- CUR,    Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
ROS↑, Bcl-2↓, PARP↑, cDC2↓, CycB/CCNB1↓, MDM2↓,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
3233- EGCG,    Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways
- in-vitro, Cerv, HeLa
DNMTs↓, DNMT1↓, DNMT3A↓, HDAC2↓, HDAC3↓, HDAC4↓, EZH2↓, PI3K↓, Wnt↓, MAPK↓, hTERT/TERT↓, MMP2↓, MMP7↓, IL6↓, MDM2↓, MMP-10↓, TP53↑, PTEN↑,
2495- Fenb,    Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
- in-vitro, Melanoma, A375
P53↑, P21↑, TumCCA↑, MDM2↓, MDMX↓, eff↑,
2852- FIS,    A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms
- Review, CRC, NA
Risk↓, P53↑, MDM2↓, COX2↓, Wnt↓, NF-kB↓, CDK2↓, CDK4↓, p‑RB1↓, cycE/CCNE↓, P21↑, NRF2↓, ROS↑, Casp8↑, Fas↑, TRAIL↑, DR5↑, MMP↓, Cyt‑c↑, selectivity↑, P450↝, GSTs↝, RadioS↑, Inflam↓, β-catenin/ZEB1↓, EGFR↓, TumCCA↑, ChemoSen↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
3343- QC,    Quercetin, a Flavonoid with Great Pharmacological Capacity
- Review, Var, NA - Review, AD, NA - Review, Arthritis, NA
*antiOx↑, *ROS↓, *angioG↓, *Inflam↓, *BioAv↓, *Half-Life↑, *GSH↑, *SOD↑, *Catalase↑, *Nrf1↑, *BP↓, *cardioP↑, *IL10↓, *TNF-α↓, *Aβ↓, *GSK‐3β↓, *tau↓, *neuroP↑, *Pain↓, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL17↓, *MCP1↓, PKCδ↓, ERK↓, BAX↓, cMyc↓, KRAS↓, ROS↓, selectivity↑, tumCV↓, Apoptosis↑, TumCCA↑, eff↑, P-gp↓, eff↑, eff↑, eff↑, eff↑, CycB/CCNB1↓, CDK1↓, CDK4↓, CDK2↓, TOP2↓, Cyt‑c↑, cl‑PARP↑, MMP↓, HSP70/HSPA5↓, HSP90↓, MDM2↓, RAS↓, eff↑,
2981- RES,    Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways
- in-vitro, Colon, HT-29 - in-vitro, Colon, SW48
TumCCA↑, p27↑, cycD1/CCND1↓, TumCP↓, IGF-1R↓, Akt↓, Wnt↓, P53↑, Apoptosis↑, Sp1/3/4↓, cl‑PARP↑, β-catenin/ZEB1↓, MDM2↓,
3003- RosA,    Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases
- Review, Var, NA - Review, AD, NA - Review, Park, NA
*Inflam↓, *antiOx↑, *neuroP↑, *IL6↓, *IL1β↓, *NF-kB↓, *PGE2↓, *COX2↓, *MMP↑, *memory↑, *ROS↓, *Aβ↓, *HMGB1↓, TumCG↓, MARK4↓, Zeb1↓, MDM2↓, BNIP3↑, ASC↑, NLRP3↓, PI3K↓, Akt↓, Casp1↓, E-cadherin↑, STAT3↓, TLR4↓, MMP↓, ICAM-1↓, AMPK↓, IL6↑, MMP2↓, Warburg↓, Bcl-xL↓, Bcl-2↓, TumCCA↑, EMT↓, TumMeta↓, mTOR↓, HSP27↓, Casp3↑, GlucoseCon↓, lactateProd↓, VEGF↓, p‑p65↓, GIT1↓, FOXM1↓, cycD1/CCND1↓, CDK4↓, MMP9↓, HDAC2↓,
2120- TQ,    Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3
- in-vitro, Melanoma, A431
ROS↑, Apoptosis↑, P53↑, BAX↑, MDM2↓, Bcl-2↓, Bcl-xL↓, Casp9↑, Casp7↑, Casp3↑, STAT3↓, cycD1/CCND1↓, survivin↓, eff↓,
4844- Uro,    Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H460
TumCMig↓, TumCI↓, EMT↓, Snail↓, MDM2↑, P53↑, E-cadherin↑, N-cadherin↓, Vim↓,
4839- Uro,    Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
tumCV↓, Apoptosis↓, P53↑, P21↑, PUMA↑, NOXA↑, MDM2↓, XIAP↓,
4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Inflam↓, IL6↓, IL1β↓, NOS2↓, p53 Wildtype↑, MDM2↑, Snail↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓, mTOR↓, p‑Akt↓, selectivity↑, EMT↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 22

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   Catalase↓, 2,   CYP1A1↓, 1,   GPx↓, 1,   GSH↓, 4,   GSR↓, 1,   GSTs↓, 1,   GSTs↝, 1,   HO-1↓, 3,   HO-1↑, 1,   HO-2↓, 1,   MDA↑, 1,   NQO1↓, 1,   NQO1↑, 1,   NRF2↓, 4,   NRF2↑, 2,   ROS↓, 2,   ROS↑, 14,   ROS⇅, 1,   SOD↓, 2,   SOD↑, 1,   SOD1↑, 1,   SOD2↓, 1,   SOD2↑, 1,   Trx1↑, 1,   TrxR↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   AIF↑, 2,   CDC2↓, 2,   CDC25↓, 3,   MMP↓, 8,   Raf↓, 1,   XIAP↓, 5,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   AMPK↓, 1,   AMPK↑, 1,   cMyc↓, 4,   p‑cMyc↑, 1,   ECAR↝, 1,   GlucoseCon↓, 2,   Glycolysis↓, 2,   HK2↓, 1,   lactateProd↓, 2,   PDK1?, 2,   PI3K/mTOR/ETS2↓, 1,   cl‑PPARα↓, 1,   SIRT1↓, 2,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 6,   Akt↑, 1,   p‑Akt↓, 5,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 7,   BAX↓, 1,   BAX↑, 9,   BAX⇅, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 10,   Bcl-xL↓, 5,   BIM↑, 1,   Casp↑, 1,   Casp1↓, 2,   Casp3↓, 2,   Casp3↑, 9,   cl‑Casp3↑, 1,   Casp7↑, 2,   Casp8↑, 6,   cl‑Casp8↑, 1,   Casp9↑, 7,   cl‑Casp9↑, 1,   proCasp9↓, 1,   Cyt‑c↑, 9,   Diablo↑, 2,   DR5↑, 5,   Fas↑, 3,   FasL↑, 2,   HGF/c-Met↓, 1,   hTERT/TERT↓, 3,   IAP1↓, 1,   iNOS↓, 2,   JNK↓, 2,   JNK↑, 1,   p‑JNK↑, 1,   MAPK↓, 3,   MAPK↑, 1,   Mcl-1↓, 3,   MDM2↓, 18,   MDM2↑, 3,   p‑MDM2↓, 1,   Myc↓, 1,   NICD↓, 1,   NOXA↑, 2,   p27↑, 4,   p38↑, 1,   p‑p38↑, 1,   PUMA↑, 2,   survivin↓, 7,   Telomerase↓, 3,   TRAIL↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 3,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   H3↓, 1,   H4↓, 1,   HATs↓, 1,   other↓, 1,   pRB↑, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   p‑eIF2α↑, 2,   ER Stress↓, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,   HSP27↓, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   BNIP3↑, 3,   LC3B-II↑, 1,   LC3II↑, 2,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

ATM↑, 1,   DNAdam↓, 1,   DNAdam↑, 2,   DNMT1↓, 1,   DNMT3A↓, 1,   DNMTs↓, 2,   MDMX↓, 1,   p16↑, 2,   P53↑, 14,   p53 Wildtype↑, 1,   PARP↑, 2,   cl‑PARP↑, 4,   PCNA↓, 4,   SIRT6↑, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK2↓, 9,   CDK4↓, 6,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 7,   cycD1/CCND1↓, 8,   cycE/CCNE↓, 4,   E2Fs↓, 1,   P21↑, 11,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 2,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State ⓘ

CD34↓, 1,   cDC2↓, 1,   CDK8↓, 1,   cFos↓, 1,   cFos↑, 1,   cMET↓, 1,   EMT↓, 7,   EMT↑, 1,   ERK↓, 5,   p‑ERK↓, 2,   FOXM1↓, 1,   FOXO↑, 1,   p‑FOXO3↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 2,   HDAC10↑, 1,   HDAC2↓, 2,   HDAC3↓, 1,   HDAC4↓, 1,   IGF-1R↓, 1,   mTOR↓, 5,   p‑mTOR↓, 1,   Nanog↓, 1,   NOTCH↓, 2,   NOTCH1↓, 2,   OCT4↓, 1,   PI3K↓, 5,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 2,   RAS↓, 3,   SOX2↓, 1,   p‑Src↓, 1,   STAT3↓, 5,   p‑STAT3↓, 2,   p‑STAT6↓, 1,   TAZ↓, 1,   TOP2↓, 3,   TumCG↓, 3,   Wnt?, 1,   Wnt↓, 4,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AEG1↓, 1,   AP-1↓, 2,   AXL↓, 1,   Ca+2↑, 2,   Ca+2↝, 1,   Cdc42↓, 1,   Cdc42↑, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 7,   FAK↓, 4,   p‑FAK↓, 1,   GIT1↓, 1,   GLI2↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   KRAS↓, 1,   MARK4↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP-10↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 9,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 8,   MMPs↓, 1,   N-cadherin↓, 6,   PDGF↓, 1,   PKCδ↓, 3,   Rac1↓, 1,   Rho↓, 2,   ROCK1↓, 1,   Slug↓, 1,   SMAD3↓, 1,   Snail↓, 6,   TGF-β↓, 2,   TIMP1↑, 1,   TIMP2↑, 3,   TumCI↓, 3,   TumCMig↓, 1,   TumCP↓, 6,   TumMeta↓, 4,   Twist↓, 3,   Tyro3↓, 1,   uPA↓, 3,   Vim↓, 4,   Vim↑, 1,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 6,   ATF4↑, 1,   EGFR↓, 4,   EGFR↑, 1,   p‑EGFR↓, 1,   Endoglin↑, 1,   Hif1a↓, 2,   VEGF↓, 7,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

NHE1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   ASC↑, 1,   CD4+↓, 1,   COX1↓, 1,   COX2↓, 7,   CXCR4↓, 1,   ICAM-1↓, 2,   IFN-γ↓, 1,   IKKα↓, 2,   IL1↓, 2,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 6,   IL6↑, 1,   IL8↓, 2,   Inflam↓, 4,   IκB↑, 1,   p‑IκB↓, 1,   JAK↓, 1,   JAK1↓, 1,   JAK2↓, 1,   MCP1↓, 1,   NF-kB↓, 13,   p‑NF-kB↑, 1,   p65↓, 1,   p‑p65↓, 2,   PD-1↓, 1,   PD-L1↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 3,  

Protein Aggregation ⓘ

NLRP3↓, 2,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   CDK6↓, 4,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 3,   ChemoSen↓, 1,   ChemoSen↑, 6,   Dose↝, 1,   Dose∅, 1,   eff↓, 3,   eff↑, 13,   Half-Life↓, 1,   MDR1↓, 1,   P450↝, 1,   RadioS↑, 6,   selectivity↑, 6,  

Clinical Biomarkers ⓘ

AR↓, 3,   CEA↓, 1,   EGFR↓, 4,   EGFR↑, 1,   p‑EGFR↓, 1,   EZH2↓, 1,   FOXM1↓, 1,   GutMicro↑, 1,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 3,   IL6↓, 6,   IL6↑, 1,   Ki-67↓, 1,   KRAS↓, 1,   Myc↓, 1,   NOS2↓, 1,   NSE↓, 1,   PD-L1↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cachexia↓, 1,   cardioP↑, 2,   chemoP↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 1,   TumVol↓, 2,   TumW↓, 2,  
Total Targets: 335

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 6,   Catalase↑, 4,   GPx↑, 2,   GSH↑, 3,   GSR↑, 1,   GSTs↑, 2,   HO-1↑, 1,   lipid-P↓, 3,   Nrf1↑, 1,   NRF2↑, 2,   ROS↓, 5,   SOD↑, 3,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 2,  

Cell Death ⓘ

Casp3↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   NO↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   HMGB1↓, 1,   IL10↓, 1,   IL10↑, 1,   IL17↓, 1,   IL1β↓, 3,   IL6↓, 1,   Inflam↓, 2,   MCP1↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 1,   eff↑, 1,   Half-Life↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

BP↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 3,   Pain↓, 1,   toxicity↓, 1,  
Total Targets: 47

Scientific Paper Hit Count for: MDM2, Double Minute 2 homolog
3 Luteolin
3 Urolithin
2 Curcumin
2 EGCG (Epigallocatechin Gallate)
1 Apigenin (mainly Parsley)
1 Artemisinin
1 Baicalein
1 Berberine
1 Ellagic acid
1 Fenbendazole
1 Fisetin
1 Piperlongumine
1 Quercetin
1 Resveratrol
1 Rosmarinic acid
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:183  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page